Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).
View Top Employees from Oasmia Pharmaceutical ABWebsite | http://www.oasmia.com |
Ticker | OASM |
Revenue | $20 million |
Funding | $31.2 million |
Employees | 35 (35 on RocketReach) |
Founded | 1999 |
Address | Vallongatan 1, Uppsala, Uppsala 752 28, SE |
Phone | (461) 850-5440 |
Fax | (461) 851-0873 |
Technologies |
JavaScript,
HTML,
PHP
+8 more
(view full list)
|
Industry | Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Pharmaceutical |
Web Rank | 4 Million |
Keywords | Oasmia Pharmaceutical, Fullmakt Pa Oasmia, Oasmia, Oasima Pharnaceutical, Oasmia Israel |
Competitors | Biosyn , Inc., CIS Pharma, Kancera, LifeCycle Pharma Inc, Poniard Pharmaceuticals , Inc. |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular Oasmia Pharmaceutical AB employee's phone or email?
The Oasmia Pharmaceutical AB annual revenue was $20 million in 2023.
Heidi Ramstad is the Chief Medical Officer of Oasmia Pharmaceutical AB.
35 people are employed at Oasmia Pharmaceutical AB.
Oasmia Pharmaceutical AB is based in Uppsala, Uppsala.
The NAICS codes for Oasmia Pharmaceutical AB are [32, 325, 32541, 3254].
The SIC codes for Oasmia Pharmaceutical AB are [283, 28].